ClinicalTrials.gg
CompletedNCT01790126Updated Mar 11, 2020Results posted

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

A Phase 2 interventional study of ARN-509 and LHRH Agonist in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
32nd of 70
90 · median 81
Started
2013
with 2 others
Phase 2
37 of 70
8 open now
Registered
2nd of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 32nd largest by enrollment, is one of 3 that started in 2013, is one of 37 in phase 2, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer. The endpoints selected reflect measurable short term effects of androgen deprivation therapy (ADT), including quality of life and several metabolic parameters. In addition, the relative effect of each treatment strategy on PSA suppression as well as testosterone recovery (and subsequent PSA progression) after 12 months of therapy will be evaluated.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • proven adenocarcinoma of the prostate
  • Rising PSA after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy with curative intent
  • PSA doubling time less than or equal to 12 months
  • No evidence of disease on imaging by whole body bone scan and computerized tomography (CT) or Magnetic Resonance Imaging (MRI) of the abdomen/pelvis within 6 weeks prior to randomization
  • Minimum PSA 1.0 ng/mL if prior radical prostatectomy +/- or salvage radiation; nadir + 2.0 ng/mL if prior RT without prior radical prostatectomy
  • Prior androgen deprivation therapy (ADT) allowed if last dose was greater than (>) 6 months prior to randomization
  • No prior androgen deprivation therapy (ADT) or anti-androgen for biochemical relapse
  • Serum testosterone > 150 ng/dL at study entry
  • No history of seizures or medical conditions which may lower seizure threshold

Key Exclusion Criteria:

  • Use of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) within 6 weeks prior to randomization
  • Use of antiandrogen (e.g. flutamide, nilutamide, bicalutamide) within 6 weeks prior to randomization
  • Prior bilateral orchiectomy
  • Prior treatment with ADT for biochemically prostate cancer. Prior ADT as neo-adjuvant, concurrent, and/or adjuvant treatment following salvage radiation therapy or prostatectomy for biochemically relapsed disease is allowed provided last dose of ADT is greater than (>) 6 months prior to randomization and the Screening serum testosterone level is greater than or equal to (≥)150 ng/dL
  • Use of systemic at an equivalent dose of prednisone 5 mg/day or higher at randomization
  • Any history of seizures or medical condition which lowers seizure threshold
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    ARN-509

    ARN-509 Tablets, 240 mg/day administered orally

    Drug: ARN-509

  • Active comparator
    LHRH agonist + ARN-509

    Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally

    Drug: ARN-509 · Drug: LHRH Agonist

  • Active comparator
    LHRH agonist

    Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).

    Drug: LHRH Agonist

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

    Time frame: Baseline, at 12 months

Secondary outcomes

  1. Change From Baseline in FACT-P Total Score at 3 and 24 Months

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

    Time frame: Baseline, at 3 and 24 months

  2. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score at 3, 12 and 24 Months

    EORTC QLQ-C30 is a 30 items self-reporting questionnaire resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related quality of life. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

    Time frame: Baseline, at 3, 12 and 24 months

  3. Change From Baseline in EORTC Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Score at 3, 12 and 24 Months

    EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It Consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions on a 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).

    Time frame: Baseline, at 3, 12 and 24 months

  4. Change From Baseline in Sexual Health Inventory for Men (SHIM) Total Score at 3, 12, 24 Months

    The SHIM is a well validated abridged 5-item of the 15-item International Index of Erectile Function, which has been extensively studied in men with erectile dysfunction due to various etiologies, including prostate cancer-related therapies. It consists of 5 items pertaining to sexual functioning, with scores ranging from 0-5 for most items. The total score is obtained by adding all five item scores, and can range from 5 to 25. Higher scores indicate higher level of sexual function and less erectile dysfunction.

    Time frame: Baseline, at 3, 12, 24 months

  5. Time to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria

    PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later.

    Time frame: Up to 24 months

  6. Percentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone

    Percentage of participants without evidence of PSA or radiographic progression during the 24-month treatment period and with recovery of serum testosterone at 24 months were reported. Testosterone recovery was defined as a serum testosterone greater than (\>) 150 nanogram per deciliter (ng/dL). PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later. Radiographic progression was defined as the detection of new metastasis on either bone scan or cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]).

    Time frame: Up to 24 months

  7. Percentage of Participants With a Serum PSA Less Than 0.2 ng/mL

    Percentage of participants with PSA less than (\<) 0.2 ng/mL after 7 months of protocol therapy were reported.

    Time frame: From 7 to 24 months

  8. Change From Baseline in Body Mass Index (BMI)

    Change from baseline in BMI was reported. BMI was calculated as 'body weight in kg/(height in meters)\* (height in meters)'. Endpoint values are from the last measurement within the analysis period.

    Time frame: Baseline, Day 1 (Cycle 1), Day 28 (Cycle 1, 2, 4, 5, 7, 8, 10 and 11), Day 35 (Cycle 3, 6, 9 and 12) and endpoint (up to 24 months)

  9. Change From Baseline in Fasting Plasma Glucose

    The change from baseline in fasting plasma glucose levels was analyzed and reported using a mixed-model for repeated measures.

    Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)

  10. Change From Baseline in Glycated Hemoglobin (HbA1C)

    The change from baseline in HbA1C was analyzed and reported using a mixed-model for repeated measures.

    Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)

  11. Change From Baseline in Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and Triglycerides

    Change from baseline in cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were analyzed and reported using a mixed-model for repeated measures.

    Time frame: Baseline, Day 35 (Cycle 3, 6, 9 and 12)

  12. Change From Baseline in Bone Mineral Density (BMD)

    Change from baseline in BMD was assessed for femoral neck and lumber spine with DEXA scans.

    Time frame: Baseline, Cycle 12 Day 35

  13. Median Time to Serum Testosterone Recovery to Greater Than (>) 50 ng/dL (Non-castrate) and > 150 ng/dL

    The time to serum testosterone recovery to \> 50 ng/dL and \> 150 ng/dL from Month 13 to Month 24 of protocol therapy was reported.

    Time frame: Month 13 to Month 24

  14. Change From Baseline in Serum Dihydrotestosterone (DHT) Levels

    Change from baseline in serum DHT levels was reported.

    Time frame: Baseline, Day 35 (Cycle 6 and Cycle 12)

  15. Change From Baseline in Estradiol Levels

    Change from baseline in estradiol levels was reported.

    Time frame: Baseline, Day 35 (Cycle 6 and Cycle 12)

  16. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events are those that occurred between the date of 1st dose of study drug and date of last dose of study drug plus 30 days.

    Time frame: From date of 1st dose of study drug to date of last dose of study drug plus 30 days (up to 6 years)

07

Results

Posted Mar 11, 2020

Participant flow

Participant flow — Overall Study
MilestoneLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Started302931
Treated292931
Completed000
Not completed302931
Withdrew: Psa progression121616
Withdrew: Other548
Withdrew: Initiation of non-protocol therapy342
Withdrew: Withdrawal by physician112
Withdrew: Withdrawal by subject312
Withdrew: Lost to follow-up101
Withdrew: Adverse event020
Withdrew: Death200
Withdrew: Radiographic progression310

Outcome measures

PrimaryChange From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

Time frame:
Baseline, at 12 months
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months
Units on a scaleLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months-8.04 ± 2.40-6.60 ± 2.53-9.42 ± 2.30
SecondaryChange From Baseline in FACT-P Total Score at 3 and 24 Months

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

Time frame:
Baseline, at 3 and 24 months
Reported as:
Least squares mean · Units on a scale
Change From Baseline in FACT-P Total Score at 3 and 24 Months
Units on a scaleLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at 3 months-2.62 ± 2.49-4.80 ± 2.45-6.72 ± 2.29
Change at 24 months-4.43 ± 2.911.84 ± 3.17-1.87 ± 2.59
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score at 3, 12 and 24 Months

EORTC QLQ-C30 is a 30 items self-reporting questionnaire resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related quality of life. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.

Time frame:
Baseline, at 3, 12 and 24 months
Reported as:
Least squares mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score at 3, 12 and 24 Months
Units on a scaleLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Appetite loss: Change at 3 months2.80 ± 2.843.43 ± 2.758.04 ± 2.48
Appetite loss: Change at 12 months3.49 ± 3.344.87 ± 3.515.70 ± 3.09
Appetite loss: Change at 24 months-2.29 ± 4.05-2.50 ± 4.355.28 ± 3.29
Cognitive functioning: Change at 3 months-2.44 ± 3.69-6.83 ± 3.62-7.73 ± 3.28
Cognitive functioning: Change at 12 months-2.21 ± 3.40-11.50 ± 3.58-8.27 ± 3.19
Cognitive functioning: Change at 24 months-5.08 ± 4.16-12.71 ± 4.64-4.42 ± 3.55
Constipation: Change at 3 months2.90 ± 3.01-3.21 ± 2.943.45 ± 2.65
Constipation: Change at 12 months10.12 ± 3.180.27 ± 3.367.69 ± 2.96
Constipation: Change at 24 months0.45 ± 4.100.91 ± 4.43-0.10 ± 3.33
Diarrhoea: Change at 3 months5.99 ± 4.268.10 ± 4.208.09 ± 3.77
Diarrhoea: Change at 12 months0.02 ± 3.660.96 ± 3.873.28 ± 3.42
Diarrhoea: Change at 24 months-0.35 ± 4.49-1.96 ± 4.974.38 ± 3.73
Dyspnoea: Change at 3 months6.42 ± 4.3613.22 ± 4.2912.85 ± 3.86
Dyspnoea: Change at 12 months4.45 ± 4.0710.32 ± 4.349.49 ± 3.82
Dyspnoea: Change at 24 months11.16 ± 5.418.89 ± 5.867.34 ± 4.42
Emotional functioning: Change at 3 months-0.81 ± 2.79-2.59 ± 2.731.41 ± 2.46
Emotional functioning: Change at 12 months1.39 ± 2.461.71 ± 2.603.84 ± 2.29
Emotional functioning: Change at 24 months-0.60 ± 3.373.59 ± 3.673.13 ± 2.77
Fatigue: Change at 3 months11.40 ± 4.3221.85 ± 4.3022.40 ± 3.80
Fatigue: Change at 12 months15.29 ± 3.9713.29 ± 4.2219.80 ± 3.70
Fatigue: Change at 24 months11.33 ± 4.965.53 ± 5.495.81 ± 4.10
Financial difficulties: Change at 3 months-5.91 ± 3.39-1.79 ± 3.332.49 ± 3.03
Financial difficulties: Change at 12 months-6.26 ± 3.493.98 ± 3.703.90 ± 3.28
Financial difficulties: Change at 24 months-10.69 ± 4.47-1.56 ± 4.88-3.90 ± 3.71
Global health status: Change at 3 months-3.57 ± 3.45-10.30 ± 3.36-9.19 ± 3.01
Global health status: Change at 12 months-4.90 ± 3.08-8.28 ± 3.23-6.08 ± 2.85
Global health status: Change at 24 months-8.14 ± 4.14-3.73 ± 4.52-7.05 ± 3.39
Insomnia: Change at 3 months6.88 ± 6.185.31 ± 6.0814.34 ± 5.46
Insomnia: Change at 12 months15.89 ± 5.462.71 ± 5.808.60 ± 5.12
Insomnia: Change at 24 months16.34 ± 6.962.49 ± 7.83-3.00 ± 5.76
Nausea and vomiting: Change at 3 months2.88 ± 1.563.62 ± 1.533.99 ± 1.38
Nausea and vomiting: Change at 12 months2.08 ± 1.342.05 ± 1.433.51 ± 1.26
Nausea and vomiting: Change at 24 months1.19 ± 1.190 ± 01.59 ± 1.09
Pain: Change at 3 months2.57 ± 4.031.63 ± 3.953.53 ± 3.56
Pain: Change at 12 months6.24 ± 3.894.41 ± 4.1114.42 ± 3.64
Pain: Change at 24 months2.84 ± 4.842.12 ± 5.212.99 ± 3.92
Physical functioning: Change at 3 months-1.68 ± 2.51-7.72 ± 2.46-3.87 ± 2.22
Physical functioning: Change at 12 months-4.90 ± 2.45-6.32 ± 2.59-6.78 ± 2.30
Physical functioning: Change at 24 months-7.08 ± 2.96-3.61 ± 3.21-3.80 ± 2.50
Role functioning: Change at 3 months-6.92 ± 3.94-4.70 ± 3.87-8.14 ± 3.48
Role functioning: Change at 12 months-6.55 ± 4.00-9.65 ± 4.24-12.12 ± 3.75
Role functioning: Change at 24 months-3.48 ± 4.990.08 ± 5.43-7.57 ± 4.06
Social functioning: Change at 3 months-5.72 ± 4.03-1.95 ± 3.96-9.57 ± 3.56
Social functioning: Change at 12 months-6.95 ± 3.69-0.37 ± 3.91-5.01 ± 3.45
Social functioning: Change at 24 months5.15 ± 4.643.90 ± 5.06-2.93 ± 3.81
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Score at 3, 12 and 24 Months

EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It Consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions on a 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).

Time frame:
Baseline, at 3, 12 and 24 months
Reported as:
Least squares mean · Units on a scale
Change From Baseline in EORTC Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Score at 3, 12 and 24 Months
Units on a scaleLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Incontinence aid: Change at 3 months21.74 ± 11.723.35 ± 14.2212.09 ± 10.97
Incontinence aid: Change at 12 months14.31 ± 9.9215.11 ± 10.072.78 ± 9.44
Incontinence aid: Change at 24 months20.60 ± 16.0432.59 ± 12.5219.46 ± 9.82
Bowel symptoms: Change at 3 months1.43 ± 1.534.27 ± 1.495.37 ± 1.33
Bowel symptoms: Change at 12 months5.11 ± 1.571.36 ± 1.693.76 ± 1.45
Bowel symptoms: Change at 24 months-0.82 ± 1.980.93 ± 2.091.48 ± 1.56
HTRS: Change at 3 months10.56 ± 2.258.09 ± 2.2113.32 ± 2.01
HTRS: Change at 12 months14.72 ± 2.4418.05 ± 2.5919.43 ± 2.30
HTRS: Change at 24 months6.42 ± 3.161.30 ± 3.455.39 ± 2.62
Sexual activity: Change at 3 months20.18 ± 4.4016.10 ± 4.3219.78 ± 3.98
Sexual activity: Change at 12 months33.50 ± 4.0319.16 ± 4.2425.02 ± 3.83
Sexual activity: Change at 24 months13.17 ± 5.2311.46 ± 5.7212.56 ± 4.39
Sexual functioning: Change at 3 months9.65 ± 9.8022.03 ± 9.0337.20 ± 10.73
Sexual functioning: Change at 12 months10.65 ± 10.09-1.19 ± 9.0510.73 ± 11.14
Sexual functioning: Change at 24 months-6.41 ± 12.5812.33 ± 11.540.32 ± 11.34
Urinary symptoms: Change at 3 months8.87 ± 2.612.55 ± 2.547.16 ± 2.28
Urinary symptoms: Change at 12 months5.47 ± 2.451.81 ± 2.5710.54 ± 2.26
Urinary symptoms: Change at 24 months5.87 ± 3.260.52 ± 3.509.16 ± 2.70
SecondaryChange From Baseline in Sexual Health Inventory for Men (SHIM) Total Score at 3, 12, 24 Months

The SHIM is a well validated abridged 5-item of the 15-item International Index of Erectile Function, which has been extensively studied in men with erectile dysfunction due to various etiologies, including prostate cancer-related therapies. It consists of 5 items pertaining to sexual functioning, with scores ranging from 0-5 for most items. The total score is obtained by adding all five item scores, and can range from 5 to 25. Higher scores indicate higher level of sexual function and less erectile dysfunction.

Time frame:
Baseline, at 3, 12, 24 months
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Sexual Health Inventory for Men (SHIM) Total Score at 3, 12, 24 Months
Units on a scaleLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at 3 months-3.64 ± 0.74-1.80 ± 0.67-3.54 ± 0.63
Change at 12 months-3.52 ± 0.81-2.91 ± 0.83-3.79 ± 0.78
Change at 24 months-1.97 ± 1.16-2.03 ± 1.17-2.39 ± 0.99
SecondaryTime to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria

PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later.

Time frame:
Up to 24 months
Reported as:
Median · Months
Time to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria
MonthsLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Time to Prostate Specific Antigen (PSA) Progression Based on Modified Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria30.88 (22.54 to NA)25.79 (20.04 to 38.90)36.11 (26.97 to 56.64)
SecondaryPercentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone

Percentage of participants without evidence of PSA or radiographic progression during the 24-month treatment period and with recovery of serum testosterone at 24 months were reported. Testosterone recovery was defined as a serum testosterone greater than (\>) 150 nanogram per deciliter (ng/dL). PSA progression was defined as a rise to greater than 50 percent (%) of the baseline serum PSA or rise of 2 nanogram per milliliter (ng/mL) or more above the nadir, whichever is higher, confirmed by repeat measurement at least 2 weeks later. Radiographic progression was defined as the detection of new metastasis on either bone scan or cross-sectional imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]).

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone
Percentage of participantsLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Percentage of Participants Without PSA or Radiographic Progression and With Recovery of Serum Testosterone19.237.037.9
SecondaryPercentage of Participants With a Serum PSA Less Than 0.2 ng/mL

Percentage of participants with PSA less than (\<) 0.2 ng/mL after 7 months of protocol therapy were reported.

Time frame:
From 7 to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With a Serum PSA Less Than 0.2 ng/mL
Percentage of participantsLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Percentage of Participants With a Serum PSA Less Than 0.2 ng/mL88.588.996.6
SecondaryChange From Baseline in Body Mass Index (BMI)

Change from baseline in BMI was reported. BMI was calculated as 'body weight in kg/(height in meters)\* (height in meters)'. Endpoint values are from the last measurement within the analysis period.

Time frame:
Baseline, Day 1 (Cycle 1), Day 28 (Cycle 1, 2, 4, 5, 7, 8, 10 and 11), Day 35 (Cycle 3, 6, 9 and 12) and endpoint (up to 24 months)
Reported as:
Mean · Kilogram per meter square (kg/m^2)
Change From Baseline in Body Mass Index (BMI)
Kilogram per meter square (kg/m^2)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at Cycle 1 Day 10.00—0.00
Change at Cycle 1 Day 280.00 ± 0.443-0.02 ± 0.569-0.29 ± 0.458
Change at Cycle 2 Day 28-0.06 ± 0.903-0.23 ± 0.616-0.32 ± 0.524
Change at Cycle 3 Day 350.02 ± 0.837-0.34 ± 0.729-0.24 ± 0.610
Change at Cycle 4 Day 280.19 ± 0.784-0.17 ± 0.710-0.12 ± 0.645
Change at Cycle 5 Day 280.26 ± 0.892-0.15 ± 0.8300.05 ± 0.716
Change at Cycle 6 Day 350.43 ± 0.851-0.15 ± 1.041-0.01 ± 0.771
Change at Cycle 7 Day 280.48 ± 0.862-0.16 ± 1.1140.07 ± 0.743
Change at Cycle 8 Day 280.56 ± 0.8800.02 ± 1.2080.15 ± 0.811
Change at Cycle 9 Day 350.58 ± 0.9190.04 ± 1.1890.06 ± 0.822
Change at Cycle 10 Day 280.66 ± 1.0590.12 ± 1.3450.20 ± 0.584
Change at Cycle 11 Day 280.63 ± 1.2270.04 ± 1.2480.24 ± 0.825
Change at Cycle 12 Day 350.66 ± 1.0490.01 ± 1.3120.15 ± 0.682
Endpoint0.65 ± 0.992-0.07 ± 1.2720.11 ± 0.705
SecondaryChange From Baseline in Fasting Plasma Glucose

The change from baseline in fasting plasma glucose levels was analyzed and reported using a mixed-model for repeated measures.

Time frame:
Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose
Millimoles per liter (mmol/L)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at Cycle 3 Day 35-0.07 ± 0.240.11 ± 0.230.61 ± 0.21
Change at Cycle 6 Day 350.19 ± 0.19-0.00 ± 0.190.27 ± 0.17
Change at Cycle 9 Day 350.10 ± 0.18-0.10 ± 0.190.41 ± 0.16
Change at Cycle 12 Day 350.29 ± 0.190.15 ± 0.190.26 ± 0.16
SecondaryChange From Baseline in Glycated Hemoglobin (HbA1C)

The change from baseline in HbA1C was analyzed and reported using a mixed-model for repeated measures.

Time frame:
Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Reported as:
Least squares mean · Percentage of HbA1C
Change From Baseline in Glycated Hemoglobin (HbA1C)
Percentage of HbA1CLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at Cycle 3 Day 350.14 ± 0.06-0.07 ± 0.060.06 ± 0.06
Change at Cycle 6 Day 350.09 ± 0.06-0.10 ± 0.060.08 ± 0.06
Change at Cycle 9 Day 350.16 ± 0.06-0.13 ± 0.060.04 ± 0.06
Change at Cycle 12 Day 350.18 ± 0.06-0.09 ± 0.060.13 ± 0.06
SecondaryChange From Baseline in Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and Triglycerides

Change from baseline in cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were analyzed and reported using a mixed-model for repeated measures.

Time frame:
Baseline, Day 35 (Cycle 3, 6, 9 and 12)
Reported as:
Least squares mean · mmol/L
Change From Baseline in Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol and Triglycerides
mmol/LLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Cholesterol: Change at Cycle 3 Day 350.34 ± 0.160.98 ± 0.161.28 ± 0.13
Cholesterol: Change at Cycle 6 Day 350.18 ± 0.160.71 ± 0.161.35 ± 0.13
Cholesterol: Change at Cycle 9 Day 350.24 ± 0.160.66 ± 0.171.21 ± 0.14
Cholesterol: Change at Cycle 12 Day 350.38 ± 0.160.71 ± 0.170.92 ± 0.15
LDL Cholesterol: Change at Cycle 3 Day 350.08 ± 0.150.67 ± 0.150.91 ± 0.13
LDL Cholesterol: Change at Cycle 6 Day 35-0.03 ± 0.150.36 ± 0.150.87 ± 0.13
LDL Cholesterol: Change at Cycle 9 Day 350.01 ± 0.140.28 ± 0.150.69 ± 0.13
LDL Cholesterol: Change at Cycle 12 Day 350.07 ± 0.150.31 ± 0.160.57 ± 0.13
HDL Cholesterol: Change at Cycle 3 Day 350.08 ± 0.040.07 ± 0.050.13 ± 0.04
HDL Cholesterol: Change at Cycle 6 Day 350.09 ± 0.040.16 ± 0.050.12 ± 0.04
HDL Cholesterol: Change at Cycle 9 Day 350.10 ± 0.050.21 ± 0.050.17 ± 0.04
HDL Cholesterol: Change at Cycle 12 Day 350.12 ± 0.050.21 ± 0.060.12 ± 0.05
Triglycerides: Change at Cycle 3 Day 350.27 ± 0.140.31 ± 0.140.34 ± 0.12
Triglycerides: Change at Cycle 6 Day 350.21 ± 0.150.14 ± 0.150.52 ± 0.13
Triglycerides: Change at Cycle 9 Day 350.30 ± 0.15-0.01 ± 0.160.53 ± 0.14
Triglycerides: Change at Cycle 12 Day 350.43 ± 0.150.08 ± 0.160.28 ± 0.13
SecondaryChange From Baseline in Bone Mineral Density (BMD)

Change from baseline in BMD was assessed for femoral neck and lumber spine with DEXA scans.

Time frame:
Baseline, Cycle 12 Day 35
Reported as:
Least squares mean · Gram per centimeter square (g/cm^2)
Change From Baseline in Bone Mineral Density (BMD)
Gram per centimeter square (g/cm^2)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Femoral Neck0.00 ± 0.030.07 ± 0.03-0.02 ± 0.02
Lumbar Spine0.00 ± 0.020.01 ± 0.02-0.06 ± 0.02
SecondaryMedian Time to Serum Testosterone Recovery to Greater Than (>) 50 ng/dL (Non-castrate) and > 150 ng/dL

The time to serum testosterone recovery to \> 50 ng/dL and \> 150 ng/dL from Month 13 to Month 24 of protocol therapy was reported.

Time frame:
Month 13 to Month 24
Reported as:
Median · Months
Median Time to Serum Testosterone Recovery to Greater Than (>) 50 ng/dL (Non-castrate) and > 150 ng/dL
MonthsLuteinizing Hormone Releasing Hormone Agonist (LHRHa)LHRHa + Apalutamide
> 50 ng/dL18.89 (18.04 to 23.95)18.10 (17.91 to 24.05)
> 150 ng/dL23.33 (18.14 to 24.87)23.98 (18.00 to 24.08)
SecondaryChange From Baseline in Serum Dihydrotestosterone (DHT) Levels

Change from baseline in serum DHT levels was reported.

Time frame:
Baseline, Day 35 (Cycle 6 and Cycle 12)
Reported as:
Least squares mean · Nanomoles per liter (nmol/L)
Change From Baseline in Serum Dihydrotestosterone (DHT) Levels
Nanomoles per liter (nmol/L)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at Cycle 6 Day 35-0.90 ± 0.260.93 ± 0.27-0.90 ± 0.23
Change at Cycle 12 Day 35-0.90 ± 0.240.86 ± 0.25-0.90 ± 0.21
SecondaryChange From Baseline in Estradiol Levels

Change from baseline in estradiol levels was reported.

Time frame:
Baseline, Day 35 (Cycle 6 and Cycle 12)
Reported as:
Least squares mean · Picomoles per liter (pmol/L)
Change From Baseline in Estradiol Levels
Picomoles per liter (pmol/L)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Change at Cycle 6 Day 35-88.63 ± 12.2487.87 ± 13.37-94.11 ± 11.58
Change at Cycle 12 Day 35-77.12 ± 13.4681.29 ± 13.88-103.01 ± 12.76
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events are those that occurred between the date of 1st dose of study drug and date of last dose of study drug plus 30 days.

Time frame:
From date of 1st dose of study drug to date of last dose of study drug plus 30 days (up to 6 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Percentage of participantsLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)96.6100.0100.0

Adverse events

Collected over Up to 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Luteinizing Hormone Releasing Hormone Agonist (LHRHa)1/29 (3.4%)3/29 (10.3%)28/29 (96.6%)
Apalutamide0/29 (0%)0/29 (0%)29/29 (100%)
LHRHa + Apalutamide0/31 (0%)5/31 (16.1%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Ventricular TachycardiaCardiac disorders1/290/290/31
VertigoEar and labyrinth disorders1/290/290/31
Device FailureProduct Issues1/290/290/31
Toxic Epidermal NecrolysisSkin and subcutaneous tissue disorders1/290/290/31
Acute Myocardial InfarctionCardiac disorders0/290/291/31
Angina PectorisCardiac disorders0/290/291/31
Atrial FibrillationCardiac disorders0/290/291/31
Wound InfectionInfections and infestations0/290/291/31
Rib FractureInjury, poisoning and procedural complications0/290/291/31
Transient Ischaemic AttackNervous system disorders0/290/291/31
Most frequent other events
Showing 10 of 70
Most frequent other events
EventLuteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + Apalutamide
Hot FlushVascular disorders25/299/2926/31
FatigueGeneral disorders22/2919/2924/31
GynaecomastiaReproductive system and breast disorders3/2912/291/31
Nipple PainReproductive system and breast disorders0/2912/290/31
InsomniaPsychiatric disorders2/291/2910/31
ArthralgiaMusculoskeletal and connective tissue disorders5/298/297/31
DiarrhoeaGastrointestinal disorders0/297/294/31
NauseaGastrointestinal disorders2/294/297/31
DysgeusiaNervous system disorders0/296/295/31
HypercholesterolaemiaMetabolism and nutrition disorders3/294/296/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + ApalutamideTotal
Mean67.3 ± 6.5166.1 ± 6.1867.5 ± 6.6767.0 ± 6.42
Sex: Female, Male
Sex: Female, Male(Participants)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + ApalutamideTotal
Female0000
Male30293190
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + ApalutamideTotal
Hispanic or Latino0303
Not Hispanic or Latino30263086
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + ApalutamideTotal
American Indian or Alaska Native0000
Asian2114
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White26262981
More than one race0000
Unknown or Not Reported2103
Region of Enrollment
Region of Enrollment(Participants)Luteinizing Hormone Releasing Hormone Agonist (LHRHa)ApalutamideLHRHa + ApalutamideTotal
UNITED STATES30293190
08

Study locations

5 sites
  • Scottsdale, Arizona, United States
  • San Francisco, California, United States
  • Chicago, Illinois, United States
  • Portland, Oregon, United States
  • Seattle, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Mar 2019, 71 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 71 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2013
First posted
Feb 13, 2013
StartActual
Mar 4, 2013
Primary completionActual
Mar 1, 2019
CompletionActual
Mar 1, 2019
Results first posted
Mar 11, 2020
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01790126
Responsible party
Sponsor
First posted
Feb 13, 2013
Start date
Mar 4, 2013
Primary completion
Mar 1, 2019
Completion
Mar 1, 2019
Results posted
Mar 11, 2020
Last update
Mar 11, 2020

Study contacts

Aragon Pharmaceuticals, Inc Clinical Trial
study director · Aragon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apalutamide · Gonadotropin-releasing Hormone Analog

Start the discussion